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We thank Grech and colleagues for their letter concerning the recently published MS-SMART 
trial. This multi-arm phase 2b trial effectively condensed, into one well powered trial, the 
study of three repurposed drugs with distinct mechanisms of action potentially relevant to 
slowing progression in secondary progressive MS (SPMS). Despite positive experimental and 
early clinical work, sadly none had any effect on slowing the rate of whole brain atrophy 
(primary outcome), nor on a variety of secondary outcome measures. 
One of our eligibility criteria was a Beck Depression Inventory II score that excluded patients 
with moderate-severe depression. Our rationale was that some of this group were likely to 
require a selective serotonin reuptake inhibitor (SSRI) during the 96 weeks of trial duration, 
and since it was fully blinded, they would have carried a 25% risk of being double-dosed. If an 
SSRI was felt to be indicated by treating neurologists, participants would therefore have 
needed to stop Investigational Medicinal Product (IMP), raising challenging ethical and 
practical issues for both participants and trial viability. Foremost in our consideration was 
recognition of the substantial investment that neuroprotective trial participants have in 
continuing to take IMP given their lack of existing therapeutic options. In effect, they would 
have been placed in the difficult position of having to choose between recommended 
treatment for their depression or hope in altering their disease trajectory through continued 
IMP dosing. Potential effects on trial viability would also have been substantial, with reduced 
dosing across all arms. Notwithstanding these difficult issues for trial design, the actual 
number who failed this screening criterion from the ineligible group were low, 7/90 (8%). 
Grech and colleagues separately raise wider questions of the potential role for SSRIs in SPMS. 
While we were specifically concerned with testing neuroprotective agents that targeted 
abnormal axonal pathobiology, we agree that there are other potentially relevant 
mechanisms of action in this clinical context. First, the well-established efficacy of SSRIs in 
treating mood disorder (symptomatic treatment) that may consequently enable people with 
SPMS to better in engage in rehabilitative or neurorestorative programmes. Secondly, a point 
that we cautiously discussed, is whether fluoxetine has any degree of ‘anti-inflammatory’ 
effect as shown by the reduction in new/enlarging T2 lesions (adjusted mean difference 
versus placebo 0.5 [95% CI 0.3-0.9; p=0.012], table 3). This might be of interest, but of course 
would need to be pursued again in an inflammatory MRI paradigm applied to an appropriately 
selected trial population with relevant outcomes.  
Our view is that there is no evidence in the broad progressing (as determined by clinical/MRI 
markers) SPMS phenotype enrolled in this study that fluoxetine has any neuroprotective 
effect: 96 week adjusted mean difference percentage brain volume change versus placebo -
0.1% [95% CI -0.5 to 0.3; p=0.86], table 2. This also concurs with the independently reported 
FLUOX-PMS study. However we would not wish to dissuade investigators from considering 
evaluation of SSRIs in the group with moderate-severe depression. 
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